Avant Sciences

About Avant Sciences

Avant Sciences is developing first-in-class retinal tamponades that evaporate post-surgery, addressing the challenges of managing residual materials in retinal procedures. This technology simplifies complex retinal surgeries and may reduce the need for additional interventions, enhancing patient outcomes.

```xml <problem> Current retinal tamponades used in retinal surgeries can be difficult to manage post-operatively, often requiring additional procedures for removal or leading to complications from residual materials. These challenges complicate surgical techniques and can negatively impact patient outcomes. </problem> <solution> Avant Sciences is developing a novel class of retinal tamponades designed to evaporate naturally after their intended use in retinal procedures. These first-in-class materials aim to simplify complex retinal surgeries by eliminating the need for secondary removal interventions. The company's lead product, evapRET, is undergoing GMP production and in-vivo pre-IDE testing. This innovative approach seeks to improve surgical efficiency and potentially reduce post-operative complications, leading to enhanced patient recovery and visual outcomes. Additional pipeline products, EOD-2, EOD-3 and EOD-4 are in various stages of preclinical development. </solution> <features> - evapRET: Evaporative retinal tamponade in GMP production and in-vivo pre-IDE testing. - EOD-2: Retinal tamponade in in-vivo pre-IDE testing. - EOD-3: Retinal tamponade in in-vitro preclinical testing. - EOD-4: Retinal tamponade in in-vivo pre-IDE testing. </features> <target_audience> The primary target audience includes vitreoretinal surgeons and hospitals performing retinal detachment repair, as well as other complex retinal surgeries. </target_audience> ```

What does Avant Sciences do?

Avant Sciences is developing first-in-class retinal tamponades that evaporate post-surgery, addressing the challenges of managing residual materials in retinal procedures. This technology simplifies complex retinal surgeries and may reduce the need for additional interventions, enhancing patient outcomes.

Where is Avant Sciences located?

Avant Sciences is based in East New York, United States.

When was Avant Sciences founded?

Avant Sciences was founded in 2023.

Location
East New York, United States
Founded
2023
0
Looking for specific startups?
Try our free semantic startup search

Avant Sciences

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Avant Sciences is developing first-in-class retinal tamponades that evaporate post-surgery, addressing the challenges of managing residual materials in retinal procedures. This technology simplifies complex retinal surgeries and may reduce the need for additional interventions, enhancing patient outcomes.

avantsci.com
Founded 2023 – East New York, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Company Description

Problem

Current retinal tamponades used in retinal surgeries can be difficult to manage post-operatively, often requiring additional procedures for removal or leading to complications from residual materials. These challenges complicate surgical techniques and can negatively impact patient outcomes.

Solution

Avant Sciences is developing a novel class of retinal tamponades designed to evaporate naturally after their intended use in retinal procedures. These first-in-class materials aim to simplify complex retinal surgeries by eliminating the need for secondary removal interventions. The company's lead product, evapRET, is undergoing GMP production and in-vivo pre-IDE testing. This innovative approach seeks to improve surgical efficiency and potentially reduce post-operative complications, leading to enhanced patient recovery and visual outcomes. Additional pipeline products, EOD-2, EOD-3 and EOD-4 are in various stages of preclinical development.

Features

evapRET: Evaporative retinal tamponade in GMP production and in-vivo pre-IDE testing.

EOD-2: Retinal tamponade in in-vivo pre-IDE testing.

EOD-3: Retinal tamponade in in-vitro preclinical testing.

EOD-4: Retinal tamponade in in-vivo pre-IDE testing.

Target Audience

The primary target audience includes vitreoretinal surgeons and hospitals performing retinal detachment repair, as well as other complex retinal surgeries.

Avant Sciences | StartupSeeker